News: $VLRX Valeritas' V-Go® Wearable Insulin Delivery Device Demonstrates 24% Reduction in Total Daily Insulin Dosage and Lower A1C Compared to Standard Insulin Treatment
BRIDGEWATER, N.J., April 08, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go ® Wearable Insulin Delivery device , today announced the V-GoAL randomized controlled trial of 415 patients across 52 sites. V-Go users ...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.